Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in Newly Diagnosed Chronic Graft Versus Host Disease
NCT06143891Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Started Jan 2024; status: active, not recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06143891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143891.